OLCAYA Trademark

Trademark Overview


On Thursday, August 28, 2025, a trademark application was filed for OLCAYA with the United States Patent and Trademark Office. The USPTO has given the OLCAYA trademark a serial number of 99363008. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, October 24, 2025. This trademark is owned by Amgen Inc.. The OLCAYA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations
olcaya

General Information


Serial Number99363008
Word MarkOLCAYA
Filing DateThursday, August 28, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, October 24, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating cancer and oncological disorders; Pharmaceutical preparations for treating inflammatory disorders, such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, respiratory system disorders, plaque psoriasis, alopecia, atopic dermatitis, autoimmune diseases; Pharmaceutical preparations for treating metabolic or skeletal disorders, such as obesity, diabetes, weight reduction and long-term weight loss maintenance, osteoporosis, increasing bone density, bone formation and growth; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular disorders, such as atherosclerosis, coronary artery disease, peripheral artery disease, carotid artery disease, aortic stenosis, hyperlipidemia, hyperlipoproteinemia(a), hypercholesterolemia, myocardial infarction, stroke, heart failure, stable or unstable angina, atrial fibrillation, and reduction of risk of major cardiovascular events; Pharmaceutical preparations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 28, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 91320-1799

Trademark Events


Event DateEvent Description
Thursday, August 28, 2025NEW APPLICATION ENTERED
Thursday, August 28, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 28, 2025APPLICATION FILING RECEIPT MAILED
Thursday, October 23, 2025ASSIGNED TO EXAMINER
Friday, October 24, 2025NON-FINAL ACTION WRITTEN
Friday, October 24, 2025NON-FINAL ACTION E-MAILED
Friday, October 24, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, October 24, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, October 24, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED